Difference between revisions of "Tegafur and uracil (UFT)"
m |
Warner-admin (talk | contribs) m (Text replacement - "[http://www.thomsonhc.com/home/dispatch Micromedex]" to "Micromedex") |
||
| (2 intermediate revisions by 2 users not shown) | |||
| Line 2: | Line 2: | ||
==General information== | ==General information== | ||
| − | Class/mechanism: Contains a fixed molar ratio (4:1) of uracil to tegafur. Tegafur is metabolized in vivo to [[Fluorouracil (5-FU)]], which is a pyrimidine analog antimetabolite that is metabolized to 5-fluoro-2'-deoxyuridine monophosphate (FdUMP) and 5-fluorouridine triphosphate (FUTP). FdUMP inhibits DNA synthesis by binding to thymidylate synthase and inhibiting production of thymidylate; FUTP interferes with RNA processing when it is mistakenly incorporated in place of uridine triphosphate (UTP). Uracil helps to maintain intracellular levels of [[Fluorouracil (5-FU)]] by inhibiting its degradation.<ref name="insert">[ | + | Class/mechanism: Contains a fixed molar ratio (4:1) of uracil to tegafur. Tegafur is metabolized in vivo to [[Fluorouracil (5-FU)]], which is a pyrimidine analog antimetabolite that is metabolized to 5-fluoro-2'-deoxyuridine monophosphate (FdUMP) and 5-fluorouridine triphosphate (FUTP). FdUMP inhibits DNA synthesis by binding to thymidylate synthase and inhibiting production of thymidylate; FUTP interferes with RNA processing when it is mistakenly incorporated in place of uridine triphosphate (UTP). Uracil helps to maintain intracellular levels of [[Fluorouracil (5-FU)]] by inhibiting its degradation.<ref name="insert">[https://hemonc.org/docs/packageinsert/uraciltegafur.pdf Uracil-tegafur (UFT) package insert]; adapted from source: [http://home.intekom.com/pharm/bm_squib/uft.html South African Electronic Package Inserts]</ref><ref>[http://home.intekom.com/pharm/bm_squib/uft.html Uracil-tegafur (UFT) information]</ref><ref>[http://www.merckserono.com/en/products/oncology/colorectal_cancer/uft/uft.html UFT manufacturer's site]</ref> |
<br>Route: PO | <br>Route: PO | ||
<br>Extravasation: n/a | <br>Extravasation: n/a | ||
| − | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as | + | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> |
==Patient safety== | ==Patient safety== | ||
| Line 16: | Line 16: | ||
**[[Rectal cancer]] | **[[Rectal cancer]] | ||
*[[Esophageal cancer]] | *[[Esophageal cancer]] | ||
| + | *[[Gastric cancer]] | ||
*[[Head and neck cancer]] | *[[Head and neck cancer]] | ||
*[[Non-small cell lung cancer]] | *[[Non-small cell lung cancer]] | ||
| Line 40: | Line 41: | ||
[[Category:Colon cancer medications]] | [[Category:Colon cancer medications]] | ||
[[Category:Esophageal cancer medications]] | [[Category:Esophageal cancer medications]] | ||
| + | [[Category:Gastric cancer medications]] | ||
[[Category:Head and neck cancer medications]] | [[Category:Head and neck cancer medications]] | ||
[[Category:Non-small cell lung cancer medications]] | [[Category:Non-small cell lung cancer medications]] | ||
Latest revision as of 01:54, 29 June 2024
Note: this drug combination is not FDA approved but is used widely in other countries.
General information
Class/mechanism: Contains a fixed molar ratio (4:1) of uracil to tegafur. Tegafur is metabolized in vivo to Fluorouracil (5-FU), which is a pyrimidine analog antimetabolite that is metabolized to 5-fluoro-2'-deoxyuridine monophosphate (FdUMP) and 5-fluorouridine triphosphate (FUTP). FdUMP inhibits DNA synthesis by binding to thymidylate synthase and inhibiting production of thymidylate; FUTP interferes with RNA processing when it is mistakenly incorporated in place of uridine triphosphate (UTP). Uracil helps to maintain intracellular levels of Fluorouracil (5-FU) by inhibiting its degradation.[1][2][3]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Patient safety
EMA has recommended that patients should be tested for the lack of the enzyme dihydropyrimidine dehydrogenase (DPD) before starting cancer treatment with fluorouracil given by injection or infusion (drip) or with the related medicines, capecitabine and tegafur.
Diseases for which it is used
Patient drug information
- Uracil-tegafur (UFT) patient information site[4]
- Macmillan Uracil-tegafur (UFT) patient information[5]
Also known as
- Generic name: tegafur-uracil
- Brand names: Ftorafur, Luporal, Tefudex, Ufur, Uftoral, Uracel
References
- Drugs
- Combination drugs
- Oral medications
- Fluoropyrimidines
- Colorectal cancer medications
- Colon cancer medications
- Esophageal cancer medications
- Gastric cancer medications
- Head and neck cancer medications
- Non-small cell lung cancer medications
- Non-small cell lung cancer, nonsquamous medications
- Rectal cancer medications
- PMDA approved drugs